dc.creator | El Moukhtari, Souhaila H. | es |
dc.creator | Garbayo, Elisa | es |
dc.creator | Fernández-Teijeiro, Ana | es |
dc.creator | Rodríguez Nogales, Carlos | es |
dc.creator | Couvreur, Patrick | es |
dc.creator | Blanco Prieto, María J. | es |
dc.date.accessioned | 2023-11-21T14:02:29Z | |
dc.date.available | 2023-11-21T14:02:29Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | El Moukhtari, S.H., Garbayo, E., Fernández-Teijeiro, A., Rodríguez Nogales, C., Couvreur, P. y Blanco Prieto, M.J. (2022). Nanomedicines and cell-based therapies for embryonal tumors of the nervous system. JOURNAL OF CONTROLLED RELEASE, 348, 553-571. https://doi.org/10.1016/j.jconrel.2022.06.010. | |
dc.identifier.issn | 0168-3659 | es |
dc.identifier.issn | 1873-4995 | es |
dc.identifier.uri | https://hdl.handle.net/11441/151193 | |
dc.description.abstract | Embryonal tumors of the nervous system are neoplasms predominantly affecting the pediatric population.
Among the most common and aggressive ones are neuroblastoma (NB) and medulloblastoma (MB). NB is a
sympathetic nervous system tumor, which is the most frequent extracranial solid pediatric cancer, usually
detected in children under two. MB originates in the cerebellum and is one of the most lethal brain tumors in
early childhood. Their tumorigenesis presents some similarities and both tumors often have treatment resistances
and poor prognosis. High-risk (HR) patients require high dose chemotherapy cocktails associated with acute and
long-term toxicities. Nanomedicine and cell therapy arise as potential solutions to improve the prognosis and
quality of life of children suffering from these tumors. Indeed, nanomedicines have been demonstrated to effi ciently reduce drug toxicity and improve drug efficacy. Moreover, these systems have been extensively studied in
cancer research over the last few decades and an increasing number of anticancer nanocarriers for adult cancer
treatment has reached the clinic. Among cell-based strategies, the clinically most advanced approach is chimeric antigen receptor (CAR) T therapy for both pathologies, which is currently under investigation in phase I/II
clinical trials. However, pediatric drug research is especially hampered due not only to ethical issues but also to
the lack of efficient pre-clinical models and the inadequate design of clinical trials. This review provides an
update on progress in the treatment of the main embryonal tumors of the nervous system using nanotechnology
and cell-based therapies and discusses key issues behind the gap between preclinical studies and clinical trials in
this specific area. Some directions to improve their translation into clinical practice and foster their development
are also provided. | es |
dc.format | application/pdf | es |
dc.format.extent | 19 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier Science BV | es |
dc.relation.ispartof | JOURNAL OF CONTROLLED RELEASE, 348, 553-571. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Medulloblastoma | es |
dc.subject | Neuroblastoma | es |
dc.subject | Nanomedicine | es |
dc.subject | Cell-based therapy | es |
dc.subject | Embryonal tumor | es |
dc.subject | Nervous system | es |
dc.title | Nanomedicines and cell-based therapies for embryonal tumors of the nervous system | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S016836592200339X?via%3Dihub | es |
dc.identifier.doi | 10.1016/j.jconrel.2022.06.010 | es |
dc.journaltitle | JOURNAL OF CONTROLLED RELEASE | es |
dc.publication.volumen | 348 | es |
dc.publication.initialPage | 553 | es |
dc.publication.endPage | 571 | es |